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Paraoxonase 1 (PON1) is a widely studied enzyme based on its protective role against poisoning by
organophosphate (OP) metabolites of specific OP insecticides and in vascular disease, as well as its use as
biomarker of diseases involving oxidative stress, inflammation and liver diseases.
This review provides an update about the current knowledge in the field of the analytical procedures that are used
for PON1 measurements. It will be specially focused on: (a) characteristics of the different substrates used for
measuring PON1, with emphasis in four aspects: toxicity, polymorphism influence, rate of hydrolysis and diagnostic
performance. And (b) the technical aspects of PON1 assays, in which the reagents and reaction conditions, sources
of variation, quality control systems, equipment and interferences with other esterases will be discussed.
The information provided in this review can contribute to a more accurate and safe measurements of PON1 in
laboratories and encourage researchers to explore the wide areas of PON1 in veterinary medicine that are still
unknown.
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Paraoxonases are a family of three enzymes called PON1,
PON2 and PON3. They have multifunctional roles in
various biochemical pathways such as protection against
oxidative damage and lipid peroxidation, contribution
to innate immunity, detoxification of reactive molecules,
bioactivation of drugs, modulation of endoplasmic reti-
culum stress and regulation of cell proliferation/apoptosis.
Since they are able to perform multiple autonomous and
often unrelated functions, they are considered as “moon-
lighting proteins” [1]. PON1 is the most studied enzyme
of the family. It is synthesized primarily in the liver and
appears mainly in serum, where is associated to high-
density lipoproteins (HDL) [2]. PON2 is located intra-
cellularly and PON3, although appears also in serum,
is around 2 orders of magnitude less abundant than
PON1 [3].
PON1 has been widely studied in human medicine with
excellent reviews produced by different research groups
[4-7]. Initially the interest on this enzyme arose from the* Correspondence: jjceron@um.es
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unless otherwise stated.toxicological point of view, by its protective role from poi-
soning by organophosphate derivates. But more recently
research has been focused on other clinical aspects such
as protective role in vascular disease as well as its use as
biomarker of diseases involving mainly three situations:
(a) oxidative stress, since PON1 protects against oxida-
tion [8]; (b) inflammation, being considered PON1 as a
negative acute phase protein [9] and (c) liver diseases,
because PON1 is synthesized in this organ [10]. In veter-
inary medicine, studies of PON1 have been traditionally
focused in bovine [11,12], however in recent years it has
gained interest in other species such as dogs [13,14], cats
[15] and horses [16].
PON1 can be measured based on its activity by spec-
trophotometric assays and also can be directly quantified
by immunological methods using specific antibodies [17].
The spectrophotometric assays based on the ability of
PON1 to hydrolyse substrates are currently more widely
used, probably due to their low cost and availability.
PON1 was named paraoxonase for its ability to hydrolyze
paraoxon (diethyl p-nitrophenyl phosphate, E600), the
toxic oxon metabolite of parathion [18]. However PON1
is considered as a promiscuous enzyme having also the
ability to hydrolyze many other substrates such as othertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ters and also lactones, which have been considered as its
primary substrates [19].
PON1 can be evaluated by its different activities, for
example its paraxonase activity (when paraoxon is used as
substrate), arylesterase activity (when a non phosphorous
arylester such as phenyl acetate or 4 (p)-nitrophenyl acet-
ate is used as substrate) or by its lactonase activity (when
5-thiobutil butyrolactone –TBBL- or other lactones such
as dihydrocoumarin are used as substrate). However, this
terminology seems not to be totally accurate from the
chemistry point of view, because “aryl” refers to any func-
tional group or substituent derived from an aromatic ring;
and therefore paraoxon could be also considered as an
arylester and included in the group of the arylesterases.
Maybe it would be more appropriate to use the general
term “PON1 activity” that can be measured by different
substrates such as paroxon, phenyl acetate, 4-nitrophenyl
acetate,TBBL or dihydrocoumarin. These substrates (Table 1)
are currently the most frequently used. However there are
other substrates such as chlorpyrifos, diazinon, sarin or
soman in the group of organophosphorous compounds
[20] and other different lactones [19,21] that can be also
employed in PON1 assays.
Currently in PON1 measurements described in litera-
ture, there is a great heterogeneity in the selection of the
substrates as well in the conditions of the assays used
with each substrate. This situation can lead to difficulties
in the comparison of values obtained by the different la-
boratories, generation of inappropriate results for not
using adequate analytical procedures, or problems in in-
terpretation due to the different substrate activity poly-
morphisms. This report will deal with two main topics:
(a) characteristics of the different substrates that can be
used for measuring PON1 activity with a special focus
on the most widely used and (b) the technical aspects of
PON1 assays.
Characteristics of the substrates
At this point, four characteristics (toxicity, polymorphism
influence, rate of hydrolysis and diagnostic performance)
of the main substrates used for PON1 measurements will
be reviewed.
Toxicity
European hazard codes for the main substrates used for
PON1 measurements appear in Table 2.
– Paraoxon. It is very unstable and extremely toxic [6]
and can cause a rapid and severe organophosphate
poisoning [22]. In addition to the European hazard
codes described in Table 2, paraoxon possesses the
European risk statements number 26 (very toxic by
inhalation), 27 (very toxic in contact with skin) and28–50 (in which there is included that may cause
cancer and hereditable genetic damage).
Paraoxon stock solutions should be handled in an
air-extraction fumehood and the operator should
take appropriate safety precautions such as wearing
a face mask and double nitrile gloves to protect
against accidental contact or inhalation of the toxic
fumes. In addition it can produce pollution to the
laboratory equipment, therefore dedicated sample
and reagent needles should be used, and waste water
receptacle as well waste disposal and pipettes should
be treated with NaOH [6,22,23]. In particular
paraoxon presents problems for automation in
biochemical analysers, since it can contaminate them
producing difficulties to perform assays for other
analytes on the same instrument, and the removal of
its traces requires the use of high concentration of
NaOH which could damage instruments [24].
Other organophosphorous such as diazinon,
chlorpyrifos, soman or sarin are also highly toxic and
therefore special cautions should be taken with them.
– Phenyl acetate. It is considered not as toxic as
paraoxon [6,25] but needs to be handled under
appropriate safe conditions. It has the Xn (harmful)
European hazard code and the European risk
statement number 22 (harmful if swallowed).
– 4- nitrophenyl acetate. It has been described as non
toxic [26] and does not have any hazard advice
according with the European hazard code.
– 5-thiobutil butyrolactone (TBBL) is considered as
not toxic [6].
– Dihydrocoumarin. In addition to have the Xn
(harmful) European hazard code, it has the
European risk statements 22–36 (which include very
toxic by inhalation and very toxic in contact with
skin), 37 (irritating to the respiratory system) and 38
(irritating to the skin).
Polymorphism influence
PON1 using paraoxon as substrate in human population
has a polymorphism of high versus low activity. There are
various genetic polymorphisms described in PON1 gene,
but the polymorphism in position 192 seems to be more
involved in the differences in PON1 activity between indi-
viduals [27,28]. This polymorphism has two isoforms:
PON1Q and PON1R. Leading to three phenotypic groups:
QQ representing low, QR intermediate and RR high en-
zyme activity of PON1 [18], that can produce significant
differences in the values of PON1 activity between QQ
and RR individuals [23].
This is a particular situation that occurs with paraoxon;
since other organophosphorus such as diazinon or sarin
showed a different polymorphism effect with a higher
hydrolytic rate with the Q than the R allele [20]. And other
Table 1 Chemical structure of the most frequently used substrates for PON1 assays



















Table 2 Toxicity of the different substrates used for PON1 measurements
Paraoxon Phenyl acetate 4-nitrophenyl acetate TBBL Dihydrocoumarin
Toxicity (European hazard code) T + (very toxic) N (dangerous
for the environment)
Xn (harmful) Non toxic Non toxic Xn (harmful)
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example:
– Phenyl acetate is hydrolyzed by PON1 phenotypes
with comparable potency [29] (Table 3). Also ELISA
and Western blot based methods utilizing PON1
antibodies confirm a high correlation between
measured PON1 concentrations and activity
measured with phenyl acetate [30,31]. However in a
study individuals with RR had 1.46 fold higher
PON1 values than QQ phenotype using phenyl
acetate as substrate [23].
– 4-nitrophenyl acetate had similar values of activity
for PON1 phenotypes when purified enzyme was used.
Although in serum these values showed higher
differences (Table 3) [29].
– TBBL has polymorphism influence, although it is
lower than when paraoxon is used as substrate. In a
previous report it was found a maximum difference
between medians of QQ and RR isoforms of 40.65%
for TBBL versus 167.82% for paraoxon [32]. In
general lactones are hydrolyzed preferentially by
either PON1R or PON1Q depending on their
structure [33].
PON1 enzyme levels can range widely even between
individuals with the same PON1 phenotype [34] and
PON1 phenotypes do not influence changes in PON1
associated with some clinical conditions such as hepatic
disease [27,35]. However in substrates highly influenced
by polymorphisms, such as paraoxon in humans, there is
a potential for obtaining false high values of PON1 in
populations with high frequency of PON1R when com-
pared with populations with high frequency of PON1Q
and vice versa [4]. Ideally in these cases comparison be-
tween values of each different phenotype would be rec-
ommended instead a global comparison of values in allTable 3 Activities of different substrates in human serum
and purified PON1 (in micromol substrate hydrolysed per
min per mg of protein)
Substrate Serum Purified enzyme
QQ RR QQ RR
Paraoxon 0.001 0.005 0.467 2.1
Phenyl acetate 1.26 1.52 845 720
4-nitrophenyl acetate 0.022 0.04 6.4 7.3
1-naphtyl acetate 0.023 0.032 <0.01 <0.01
Adapted from [29].population, fact that would complicate the interpretation
of the results [36,37].
There are not many studies about polymorphism in
veterinary medicine. This is in contrast with the situ-
ation in humans, in which it is a very widely studied
topic with methods (i.e. two-substrate assay) developed
to explore and differentiate PON1 activity polymor-
phisms [18]. Rabbits possess a serum polymorphism
which is located within exon 4 producing two different
phenotypes (rPON1A and rPON1B) that have the same
activity for phenyl acetate, but different values for para-
oxon, dihydrocoumarin and other lactones [38]. And
contrarily to humans, individual variations of PON1 in
pigs with phenyl acetate are genetically determined, and
phenotypes with high, intermediate and low PON1 ac-
tivity against this substrate were described [39,40]. Also
there have been evidences that variations in plasma PON1
activity in cattle could be genetically determined [41]. To
the author’s knowledge no studies to fully characterize
polymorphisms have been undertaken in other species.
Therefore studies made with populations should be taken
with caution in veterinary medicine.
Rate of hydrolysis
In humans, rate of PON1 hydrolysis of paraoxon is lower
compared with other substrates such as phenyl acetate or
4-nitrophenyl acetate (633 and 29 times higher respect-
ively) [42] and even compared with other organophos-
phorus compounds such as diazoxon or chlorpyrifos oxon
[43]. Similar results were obtained by other authors
[26,29]. These last authors made a complete study in
which the rate of hydrolysis of different substrates were
compared in serum and with purified enzyme for the two
different genotypes (Table 3). In this table it can be ob-
served that most of the activity when using paraxon,
phenyl acetate and 4-nitrophenyl acetate substrates in
serum is due to PON1; since there is enrichment in the
activity when the enzyme is purified. However, when other
substrates such as 1-naphtyl acetate are used, hydrolysis in
serum is probably due to other different esterases, since
purified PON1 does not hydrolyse this substrate.
The low hydrolysis rate of paraoxon has lead to some
authors to indicate that it could be inappropriate to call
the enzyme “paraoxonase” or “organophosphatase” [29].
Even PON1 has been considered as a good example of
the power of language to mislead, because the focus of the
name on one aspect of the enzyme’s function, which is re-
lated with its behaviour with synthetic and exogenous sub-
strates (organophosphorous compounds), has delayed an
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vant roles, that are more related with natural and en-
dogenous substrates such lactones [44].
In veterinary, although few data are available, it seems
that PON1 can have a different spectrum of activities not
only to different substrates but also to the same substrate,
depending on the species. For example minipig, rabbit and
mouse have higher rate of 4-nitrophenyl acetate hydrolysis
than rat, monkey or dog (Table 4). Regarding the inter-
species variations of the activities of different substrates, in
general 4-nitrophenyl acetate is hydrolyzed at a higher rate
than paraoxon [45,46]. And in pigs 4-nitrophenyl acetate
has eight times higher rate of hydrolysis than phenyl acet-
ate; whereas in sheep and dogs phenyl acetate is hydro-
lysed at a higher rate than 4-nitrophenyl acetate [41,46-48].
Although the lactones are considered natural substrates,
and therefore would better reflect the physiological activity
of PON1, highly correlated activities were found in
humans using TBBL and phenyl acetate; and both were
inhibited in the same manner by selective competitive
inhibitors of PON1’s activity such as 2-hydroxyquinoline
and EDTA [19]. This could explain the high correlation
when using phenyl acetate and TBBL observed in human
studies [50], bovine [51] and dog [48]. In this later study in
dogs, TBBL, phenyl acetate and 4-nitrophenyl acetate
showed significant correlations with r higher than 0.85 in
all cases. Maybe an explanation for these results is the fact
that both the activity of PON1 against lactones and phenyl
acetate or 4-phenyl acetate derivates are mediated by the
same active site of the enzyme, which is different than the
site where is the activity against phosphorous agents [52].
Diagnostic performance
In studies in which different substrates have been com-
pared, two situations can be found:
a) Conditions or diseases in which the substrates give
similar information For example:
In human medicine decreases of similar magnitude on
PON1 activity in humans with HIV using paraoxon and
TBBL (1.21 versus 1.28 fold) have been found [53]. AndTable 4 Rate of hydrolysis of 4-nitrophenyl acetate in








Rat 2.5TBBL diagnostic accuracy was similar than paraoxon to
diagnose liver failure [32].
In veterinary, similar diagnostic performance was de-
tected between dihydrocoumarin, phenyl acetate and
paraoxon for diagnosis of fatty liver in cows [51].
In the conditions of the point “a” the logical approach
would be to choose the substrate that would be less
toxic, less expensive and readily adapted to analytical in-
struments and conditions of the lab.
b) Conditions or diseases in which there can be diver-
gences between substrates In a human study comparing
paraoxon, phenyl acetate and 4-nitrophenyl acetate, the
last one was the only that showed significant changes
between patients with non-end-stage chronic renal fail-
ure and healthy individuals. This substrate showed
higher activities between narrower ranges of population
values that could probably reflect less analytical errors
[26]. In other study phenyl acetate was found to be more
sensitive and specific substrate in identifying patients
with chronic hepatic disease than paraoxon [27]. And a
stronger association between decreased serum PON1 ac-
tivity and metabolic syndrome was found in childhood
obesity when TBBL was used as substrate compared to
paraoxon [54].
In dogs higher significance in the differences between
dogs with oxidative damage and healthy dogs was found
with 4-nitrophenyl acetate compared with phenyl acetate
or TBBL [48].
Technical aspects of the assays
Setting up the assay: reagents and reaction conditions
The principle of the spectrophotometric determination
of PON1 activity is simple. The sample is mixed with a
substrate dissolved in a buffer solution, and the product
generated by the hydrolysis of the substrate is moni-
tored during certain time at a linear rate and defined
temperature. However there is a heterogeneicity in the
concentration of reagents used and assay conditions in
general.
– Buffers. The most used is Tris–HCl, but other
buffers such as glycine have been also used [26]. The
ideal pH of the reaction is in the range of 8 and 8.5
[18,55]. Since below pH 8 there is a significant
decrease in PON1 activity, whereas at values higher
than 8.5 the non-specific esterase activity of the
albumin starts to be activated [55]. Additionally also
very basic pH buffers can lead to alterations of
PON1 structure and activity [56]. Therefore those
assays that use values out of this pH range, as 7 or
10.5 should be interpreted with caution.
– Substrate concentration. There is a wide variation in
the concentration of substrates used in the assays
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ranges from 1 to 5 mmol/L, phenyl acetate from 0.2
to 6.64 mM, 4-nitrophenyl acetate from 0.5 to
2.5 mM (although a report indicated 27.6 mM [29])
and TBBL from 0.25 to 0.5 mmol.
The concentration of the substrate should be established
and optimised together with sample volume to assure the
linearity of the reaction; avoiding substrate consumption.
Ideally this concentration should be high enough than Km
in order to produce the maximum velocity, in which the
substrate is saturating the enzyme and the activity only
depends of the amount of the enzyme in the sample
(Table 5). However the substrate concentration should
not be too high; since further increases in substrate con-
centrations after these saturating conditions will not
have any effect on the kinetic of the reaction, but pro-
duce higher non-enzymatic hydrolysis. In some cases
saturating conditions are difficult to be reached during
the limited solubility of substrates, as has been described
with paraoxon [57]; therefore in this case substrate con-
centrations should at least assure the linearity of reaction.
Some substrates require an organic solvent to be dis-
solved. In these cases methanol is recommended instead
acetone since it is less inhibitory for PON1. For example
at final methanol concentrations of the assay between 1-
2%, inhibition is negligible, whereas acetone produces a
reduction of at least 25% [61]. In case of TBBL, DTNB is
also added to the assay mixture in order to colorimetri-
cally detect the released thiol moities of this substrate by
PON1 activity [52].
Usually the substrates are mixed and used together with
the buffer. But in some cases such as with 4-nitrophenyl
acetate, to avoid spontaneous hydrolysis, it is important to
remove the substrate from the working reagent buffer
and prepare it in water as a separate starting reagent.Table 5 Km (concentration of substrate that produces
half of the maximum velocity of the reaction) and
wavelengths (גּ) used for different substrates of PON1
Substrate Km (mM) Reference גּ (nm)
Paraoxon 1.2 ± 0.2 [58] 412
1.4 [59] 405
0.8 ± 0.1 [60] 405
Phenyl acetate 0.73 ± 0.08 [58] 270
1.2 ± 0.2 [60] 270
4- nitrophenyl acetate 1.5 ± 0.2 [60] 405
TBBL 2.8 [33] 412 (detected
with DTNB)0.27 ± 0.04 [52]
dihydrocumarin 0.02 [33]
270
0.129 ± 0.008 [60]This reagent remains colourless and is added to initiate
the kinetic reaction [23,48].
In order to evaluate the spontaneous hydrolysis of sub-
strates and correct the results accordingly, the use of a
blank without serum is highly recommended. This value
should be lower than 5% of the enzymatic hydrolysis rate
[52]. If this spontaneous hydrolysis is abnormally high,
new substrate should be prepared. Also the use of a
blank without substrate would be recommended.
Optimal wavelengths for different substrates appear in
Table 5. It is important to point out that not all standard
spectrophotometers or automated analysers have available
the 270 nm wavelength; so substrates with this wavelength
cannot be automated or used in certain instruments. Also
for wavelengths in the ultraviolet region (lower than
400 nm) quartz cuvettes will be required. Use of non-
optimal wavelengths can produce increase in impreci-
sion of the assay [23].
– CaCl2. PON1 has two calcium binding sites, one is
important for the stability of the enzyme while the
other one is important for the catalytic activity.
Therefore, PON1 is a calcium dependent enzyme,
and the addition of Ca in order to secure adequate
expression of enzyme activity is recommended for
the assays [62]. Usually the ranges of CaCl2 vary
from 0.9 to 3.6 mm/L. In humans using chlorpyrifos
as substrate it has been reported that PON1 activity
increases when CaCl2 is added up to 1 mM CaCl2,
where higher concentrations did not produce
further increases in activity [55]. In some species
such as rabbit low Ca concentrations in assay can
have a significant influence on PON1 activity [63],
so it would be recommended to optimize CaCl2
concentrations in the methods used.
– NaCl. Although used for phenotype characterization
with paroxon as substrate, the addition of NaCl is
not recommended for measurements at population
level. Because although it produces increases in
PON1 activity, it will stimulate much more the
high-activity allelic form [55] and therefore would
yield a higher variability in a healthy population.
When using other substrates such as phenyl acetate,
NaCl produces a decrease in PON1 activity [64].
– Time of reading. The time of readings should fulfil 3
requirements: (1) leave an initial phase without
measurements in order to avoid the other esterases
influence that can occur at this stage. (2) Be
established in coordination with the concentration
of substrate to assure that during this time a linear
phase in the reaction can be produced. If substrate
is used up, the enzyme’s active sites are no longer
saturated and linearity can be lost; therefore
substrate concentration and/or times of reaction
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represent adequately a phase with linearity, with
various measurements during at least one minute in
order to calculate the kinetics of the enzyme [25].
Usually the units in which PON1 activity is
expressed are referred in minutes, being the most
common unit used the U/L or mL of serum (U is
the abbreviation of unit of enzyme activity, and is
defined as the amount of the enzyme that catalyzes
the conversion of 1 micro mole of substrate per
minute).
– Temperature. Usually the temperatures used are in
the range of 25°C to 37°C, with higher PON1 values
found at 37°C. An increase of temperature by 1°C is
associated with a 4.5% increase in PON1 activity
using phenyl acetate as substrate [34]. Optimum
temperature for paraoxon and phenyl acetate has
been found in the range of 30-45°C [58]. However it
would not be recommended to use temperatures
higher than 37°C since it can increase substrate
non-enzymatic hydrolysis.
The measurements made at room temperature may
be subjected to temperature fluctuations. In order
to avoid these fluctuations in case of use ELISA mi-
croplates, it is recommended to ensure temperature
stabilization by setting the microplate spectropho-
tometer temperature to some level slightly higher
than typical room temperature [34].
Sources of variation due to the sample (dilution,
anticoagulants, hemolysis, lipemia, bilirrubinemia)
In some cases a dilution of the sample is needed to
maintain the reaction linearity and not produce early
substrate depletion. If this dilution procedure cannot
be automated the efficiency of routine analysis could
be reduced [65], and also this is a source of pipetting
imprecision. In addition, high dilutions can produce
increases in PON1 activities in human serum (i.e.
PON1 activity had an increase of 170% after 128 fold
dilution) [66]. This could be particularly important in
some assays using phenyl acetate in human serum,
that have to dilute the samples 800 times because of
high activity [67]. Maybe this effect could be reduced
or neglected at lower dilutions, for example no signifi-
cant increases after 1:40 dilution of dog serum were
observed [48].
Ideally serum samples should be analyzed. PON1 has
an absolute requirement for Ca2+ for activity and stability,
so use of EDTA inactivates PON1 [68]. Previous studies
found a significant decrease in PON1 activity when
EDTA-treated plasma was used instead of serum in
humans [69] and dogs [48]. Also it has been reported
that lithium inhibits PON1 activity [70]. In a previous
study, PON1 values with lithium heparin were around5% lower than compared with serum [71]. This effect
can be increased in cases that tubes are not filled ad-
equately and therefore have a higher concentration of
anticoagulant. Also in a different study, PON1 activity
was between 21-26% higher in serum that in hepari-
nised plasma, although enzyme activity in both types of
samples were highly correlated [34]. In this study it was
not specified if lithium heparin was used, and authors
suggested that fibrin clots retain water, resulting in
slightly higher serum concentrations. Therefore in case
of use lithium-heparin, results are not equivalent to
serum samples, so care should be taken when comparing
data from both types of samples [71]. Caution also should
be taken if sodium citrate is used as anticoagulant since
it chelates calcium and also involves a dilution 1:9 of
the blood [72], facts that potentially could affect PON1
activity.
The effects of the haemolysis and lipemia seem to be
different depending on the assay used. For example in
an study made in dogs in which different assays were
compared, a significant decrease in PON1 was obtained
with concentration of haemoglobin higher than 8 g/dl
(that represents a very severe haemolysis) and triglycerides
higher than 5 g/L when using TBBL as substrate. Similar
interferences were obtained for triglycerides with an assay
using phenyl acetate, however this assay was not affected
by haemoglobin. And the assay using 4-nitrophenyl
acetate as substrate showed decreases in PON1 when
haemoglobin concentration was higher than 8 g/dl and
triglycerides were higher than 1.25 g/L [48]. Overall it
seems that only very severe haemolysis affects PON1 ac-
tivity; similarly to described in humans where no sub-
stantial interferences by haemoglobin up to 6 g/L were
found using TBBL [32]. This report also concluded that
lipidemia and jaundice do not appear to have major in-
fluence on the TBBL assay.
Quality control systems
To the author’s knowledge there is no available control
serum for PON1 measurements. An alternative approach
can be the use of frozen aliquots of serum as control.
Ideally two serum pools, one with values inside the ref-
erence range and one with low values of PON1, from
the species to be measured, could be used as controls.
These control samples could be analysed just before the
beginning, at the end and at intermediate points, in case
of analyse a high number of samples. In case of human
serum, pools of different phenotypes (QQ, QR and RR)
at different activity ranges have been used for quality
control [23].
Regarding the stability of these samples, in a study
made in humans it was found that PON1 is stable dur-
ing two years at -80°C when phenyl acetate, diazoxon
and chlorpyrifos-oxon where used as substrates, but with
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storage was found [34]. In the same study, after 5 years
of storage at -80°C, the enzyme activities were 17.1%,
39.4% and 37.6% lower for phenyl acetate, chlorpyrifos-
oxon and paraoxon respectively and 22.9% higher for
diazoxon. And no significant changes with any of the
substrates after multiple freeze-thaw cycles (up to 4) in
samples stored 2 years at -80°C were found.Equipment
PON1 assays can be measured using different equipments
such as single sample spectrophotometers, microplate
readers or automated analysers.
Automated analysers allow high-throughtput measure-
ments, however they have limitations in two situations:
(a) some of them do not have available the wavelengths
required for the measurement of selected substrates,
(b) contamination can occur when paroxon or other
organophosphorous compounds are used as substrates
as previously discussed. Also in case of TBBL, a solu-
tion needs to be prepared in acetonitrile for its disolu-
tion, reaching in reaction mixtures a concentration of
around 1%, which can produce carryover contamination
by acetonitrile and may interfere with several routine
chemistries [6].
For those substrates that can contaminate automated
analysers or that need wavelengths that are not included in
conventional analysers, microplate-based methods could
be an alternative allowing high-throughput measurement
of PON1 activity. For example human assays using para-
oxon, diazinon, phenyl acetate or TBBL as substrates [18]
and dogs assays for phenyl acetate or TBBL [48] have been
adapted to microtiter 96-well plate systems. These ana-
lyses can be performed semi-automatically, are fast and fa-
cilitate a relatively high analytical throughput [6]. In case
of using paraoxon with these systems, substrate contamin-
ation should be removed by immersion of plates and pip-
ette tips in 2 mol/L NaOH [24]. And in case of using
TBBL, the samples should be analyzed in the same batch
in order to avoid the high interassay variations of this
assay that can reach up to 17% both in dogs [48] and
humans [32].Interferences with other esterases
Most of the substrates used for PON1 measurements
are esters (i.e. paraoxon is an organophosphorous ester
and the lactones are cyclic esters) that are hydrolyzed by
this enzyme. However in plasma there are other esterases
such as albumin, cholinesterases (acetyl and/or butyril)
or carboxylesterase that can carry out ester hydrolysis
[73,49]. Also carbonic anhydrase, alpha-chymotrypsin
[74] and lipase [56] can hydrolyse ester substrates. All
these esterases should be taken in consideration sincethey could potentially interfere in the determinations of
PON1.
– The effect of albumin is particularly important at
pH values higher than 8.5, where the non-specific
esterase activity of the albumin starts to be
activated [55].
– It was described that acetylcholinesterase does not
affect PON1 activity [56]. However in pigs
butyrilcholinesterase (BChE) can hydrolyse PON1
substrates such as phenyl acetate; and although
PON1 is 100 times more active toward this
substrate than cholinesterase, this activity can be
apparent in cases of pigs with very low PON1
activity [39,40]. In humans the contribution of the
hydrolysis of phenyl acetate by BChE is about 5% of
the total activity in serum [29].
– Human, monkey, dog or minipig plasmas do not
contain any carboxylesterase, however this esterase
should be taken in consideration in other species
such as rabbit, mouse and rat in which it is the
major component of the plasma [49].
– Carbonic anhydrase seems not to be at high
concentrations in serum since is a tisular enzyme [75].
– Alpha-chymoptrypsin activity was described to be
low in the phase of the reaction that usually is taken
for PON1 measurements [74].
– We could not find any report about the effect of
lipase in the substrates used for PON1 activity.
However in situations where lipase is high such
as pancreatitis, PON1 is low, therefore it seems
that lipase would not have a major effect in this
enzyme [76,77].
The activity of esterases different than PON1 can
cause a non-linear phase in the reaction that usually oc-
curs as an early burst in the first 15 to 30 seconds of the
assay, but in some cases it can last until 15 minutes. For
example using paraoxon as substrate, it was found that
10% of the samples assayed showed nonlinear kinetics
during the first 15 min of the assay, linearity being
established only after this time [78]. It is not clear which
esterase/s produce this reaction since albumin was con-
sidered [24], but other authors pointed out that albumin
preparations can be contaminated with BChE that would
produce the reaction [79,80]. Also alpha-chymotrypsin
produces an initial and rapid hydrolysis of the esters
substrates [74].
Although there is a paucity of data about the magni-
tude of the hydrolysis of the different substrates by other
esters different than PON1 that can appear in serum, it
was described that PON1 splits esters of phenols at a
higher rate than any other esterase type [41]. In this line,
when using 4-phenyl acetate, it seems that there is no
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sheep and goat, since no decrease in activity was detected
after incubation of the sample with low concentration of
paraoxon that would inhibit other estereases different than
PON1. Also minor amounts of esterases different than
PON1 appeared in rabbit and cat. However, horses have a
significant amount (around 1/3 of the total activity), and
rat, guinea pig and duck have a predominance of other
esterases in serum [45].
Two strategies have been recommended to reduce the
effect of the non-specific activity of esterases different
than PON1:
– Data collection of readings should be made when
the linear phase of the reaction starts, which usually
occurs after some period of time. But it should not
be done at zero time because it can lead to
non-linear kinetics due to the activity of other
esterases and overestimation of PON1 activity.
– The measurements should be performed at pH not
higher than 8.5 since albumin does not have esterase
activity at these pHs [55].
Conclusions and general recommendations
Although there is still a need of more knowledge in this
subject, from a general point of view, in case of PON1
measurements it could be recommended:
1. Try to select the most appropriate substrate in
terms of clinical sensitivity-specificity, less toxicity
and less polymorphism influence. At this point
much more works about clinical sensitivity-
specificity of different substrates in different species
and clinical situations, as well the influence of
polymorphism in these substrates (with the potential
development of two-substrate assays for evaluating
possible polymorphisms) would be welcome.
2. Set up adequate conditions for enzymatic reactions
to avoid situations that can negatively affect
measurements such as: very high pHs, too high
substrate concentrations, inadequate wavelengths, or
measurement in the non linear phase or the
reaction.
Possibly in the future, the use of assays that can directly
quantify the amount of PON1 would provide additional
information to the spectrophotometric assays, as occurs in
humans. For example in metabolic syndrome the finding
of unmodified PON1 protein concentration and decrease
in PON1 activity supports that PON1 is inactivated by
oxidized lipids [54].
We hope that the information provided in this review
can contribute to a more accurate and safer measurements
of PON1 in laboratories already measuring or that areplanning to set-up this assay in the future. It could also
help to a more homogenous measurement of this enzyme
and therefore the possibility of comparing values between
different laboratories; since it has been observed a high re-
producibility of these assays at different laboratories using
the same analytical conditions and standardized protocols
[34]. There is certainly a need of further studies in order
to elucidate the role of PON1 in many clinical conditions
related with oxidative stress and inflammation, as well its
use of biomarker for diagnosis, monitoring and treatment
of these diseases. And overall this review could encourage
researchers to explore the wide areas of PON1 in veterin-
ary medicine that are still unknown.
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